GlassScriptPhysician profile
Brent A Smith
NPI 1306286091
$1,578.25
in general payments reported to CMS, 2019-2025
14 companies · $159 in 2025
The $159 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2020: $53.82 · 2021: $235 · 2022: $356 · 2023: $474 · 2024: $163 · 2025: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $796.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $796.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $304.89 | 2022-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $257.08 | 2022-2025 | Miebo, Xiidra, Infuse |
| Coopervision INC. | $225.20 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens |
| Sun Pharmaceutical Industries INC. | $155.23 | 2019-2024 | Cequa |
| Alcon Vision LLC | $133.19 | 2019-2024 | Total30, Precision 1 |
| Oyster Point Pharma, INC. | $132.82 | 2022-2023 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $128.41 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $86.22 | 2021 | |
| Allergan, INC. | $41.02 | 2021 | |
| Dompe US, INC. | $33.81 | 2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $28.33 | 2024 | Xdemvy |
| Shire North American Group INC | $22.81 | 2019 | |
| Kala Pharmaceuticals, INC. | $14.64 | 2021 | |
| Eyevance Pharmaceuticals LLC | $14.60 | 2023 | Flarex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brent Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.